Neurocrine Biosciences, Inc.
DE ˙ DB ˙ US64125C1099
134,65 € ↑0,30 (0,22%)
2026-06-03
DEL PRIS
SecurityDE:NB3 / Neurocrine Biosciences, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership1,219,196 shares
Latest Disclosed Value $ 160,617,060
Morgan Stanley reports 0.81% increase in ownership of NB3 / Neurocrine Biosciences, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 1,219,196 shares of Neurocrine Biosciences, Inc. (DE:NB3) valued at $136,245,153 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 1,209,378 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 0.81% during the quarter. The current value of the position is $164,164,741 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,219,196 9,818 0.81 160,617 -6.36 0.0097
2026-05-27 2025-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 1,209,378 -617,559 -33.80 171,527 -33.12 0.0102
2026-02-13 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,209,378 -617,559 171,527 0.0102
2026-05-27 2025-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 1,826,937 7,192 0.40 256,466 12.13 0.0155
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,826,937 7,192 256,466 0.0155
2025-08-15 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,819,745 301,508 19.86 228,724 36.21 0.0149
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,518,237 -55,060 -3.50 167,917 -21.81 0.0120
2025-05-15 2024-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 1,573,297 223,916 16.59 214,756 38.13 0.0150
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,573,297 223,916 214,756 0.0150
2025-05-14 2024-09-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 1,349,381 -195,488 -12.65 155,476 -26.90 0.0113
2025-02-14 2024-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 1,349,381 -195,488 155,476 0.0113
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,349,381 -195,488 155,476 0.0113
2025-05-14 2024-06-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 1,544,869 -520,767 -25.21 212,682 -25.35 0.0165
2024-10-17 2024-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 1,544,869 -520,767 212,682 0.0165
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,544,869 -520,767 212,682 0.0165
2024-10-17 2024-03-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 2,065,636 -260,658 -11.20 284,893 -7.05 0.0229
2024-08-16 2024-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 2,065,636 -260,658 284,893 0.0229
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,065,636 -260,658 284,893 0.0229
2024-08-16 2023-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 2,326,294 402,215 20.90 306,513 41.60 0.0270
2024-02-13 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,326,294 402,215 306,513 0.0270
2023-11-15 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,924,079 56,054 3.00 216,459 22.88 0.0220
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,868,025 213,132 12.88 176,155 5.16 0.0174
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,654,893 -393,192 -19.20 167,508 -31.52 0.0180
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,048,085 1,511,307 281.55 244,623 329.09 0.0278
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 536,778 49,503 10.16 57,010 20.02 0.0078
2022-10-27 2022-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 487,275 310,448 175.57 47,500 186.54 0.0062
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 487,275 310,448 47,500 0.0012
2022-10-27 2022-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 176,827 37,462 26.88 16,577 39.64 0.0022
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 176,827 37,462 16,577 0.0022
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 139,365 -5,526 -3.81 11,871 -14.58 0.0015
2021-11-15 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 144,891 -204,709 -58.56 13,898 -59.15 0.0019
2021-08-23 2021-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 349,600 239,383 217.19 34,023 217.44 0.0045
2021-08-16 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 349,600 239,383 34,023 0.0009
2021-05-17 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 110,217 -14,856 -11.88 10,718 -10.60 0.0016
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 125,073 -158,109 -55.83 11,989 -55.97 0.0019
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 283,182 137,503 94.39 27,230 53.21 0.0053
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 145,679 64,248 78.90 17,773 152.17 0.0039
2020-05-26 2020-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 81,431 -78,068 -48.95 7,048 -58.89 0.0019
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 81,431 -78,068 7,048 541.4333
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 159,499 76,616 92.44 17,144 129.57 0.0040
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 82,883 24,210 41.26 7,468 50.75 0.0020
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 58,673 -30,376 -34.11 4,954 -36.86 0.0013
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 89,049 -67,329 -43.06 7,846 -29.74 0.0022
2019-02-14 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 156,378 -57,390 -26.85 11,167 -57.51 0.0033
2019-04-23 2018-09-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 213,768 117,168 121.29 26,283 176.95 0.0066
2018-11-20 2018-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 213,768 0 26,283 0.0066
2018-11-14 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 213,768 117,168 26,283
2019-04-23 2018-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 96,600 -88,201 -47.73 9,490 -38.08 0.0026
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 96,600 -88,201 9,490
2019-04-23 2018-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 184,801 133,621 261.08 15,326 285.95 0.0043
2018-05-14 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 184,801 133,621 15,326
2019-04-23 2017-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 51,180 14,805 40.70 3,971 78.07 0.0011
2018-02-14 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 51,180 14,805 3,971
2017-11-14 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 36,375 -16,522 -31.23 2,230 -8.42 0.0007
2017-08-11 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 52,897 22,094 71.73 2,435 82.40 0.0007
2017-05-22 2017-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 30,803 -16,570 -34.98 1,335 -27.13 0.0004
2017-05-12 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 30,803 1,335
2017-02-22 2016-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 47,373 6,605 16.20 1,832 -11.28 0.0006
2017-02-13 2016-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 47,373 1,832
2016-11-10 2016-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 40,768 -23,582 -36.65 2,065 -29.35 0.0007
2016-08-12 2016-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 64,350 26,900 71.83 2,923 97.23 0.0011
2016-05-12 2016-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 37,450 -28,243 -42.99 1,482 -60.12 0.0006
2016-02-09 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 65,693 18,767 39.99 3,716 99.04 0.0013
2016-02-08 2015-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 46,926 16,076 52.11 1,867 26.75 0.0007
2015-11-09 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 46,926 1,867
2015-08-12 2015-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 30,850 -73,786 -70.52 1,473 -64.55 0.0005
2015-05-14 2015-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 104,636 6,095 6.19 4,155 88.86 0.0015
2015-02-13 2014-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 98,541 48,368 96.40 2,200 179.54 0.0008
2014-12-16 2014-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 50,173 29,053 137.56 787 131.47 0.0003
2014-11-14 2014-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 50,173 787
2014-05-13 2014-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 21,120 -28,878 -57.76 340 -27.19 0.0001
2014-02-13 2013-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 49,998 3,987 8.67 467 -10.19 0.0002
2013-11-13 2013-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 46,011 -23,657 -33.96 520 -44.21 0.0002
2013-08-08 2013-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 69,668 69,668 932 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.